加强代谢综合征与慢性肝病关系的研究

范建高; 朱婵艳

doi:10.3969/j.issn.1001-5256.2013.12.001

加强代谢综合征与慢性肝病关系的研究

DOI: 10.3969/j.issn.1001-5256.2013.12.001

上海交通大学医学院附属新华医院消化内科

详细信息

中图分类号: R589
计量
- 文章访问数: 1994
- HTML全文浏览量: 16
- PDF下载量: 632
- 被引次数: 0
出版历程
- 收稿日期: 2013-08-05
- 出版日期: 2013-12-20

Strengthening research on relationship between metabolic syndrome and chronic liver disease

Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine

摘要

摘要: 当前代谢综合征正呈全球化的流行趋势,并已成为我国慢性肝病愈来愈重要的病因或诱因。最近大量研究表明,代谢综合征不但是非酒精性脂肪性肝病发生发展的重要危险因素,还与酒精性肝病、慢性乙型肝炎、慢性丙型肝炎以及隐源性肝病患者肝硬化和肝癌的高发密切相关。此外,合并代谢综合征的慢性肝病患者发生2型糖尿病和动脉粥样硬化性心血管疾病的危险性显著增加。提示肝病医生需加强代谢综合征与肝病的关系及其诊疗对策的临床研究。
- 代谢综合征X /
- 肥胖症,病态 /
- 肝疾病
Abstract: Metabolic syndrome is becoming a global epidemic disease, and it has been an important cause or risk factor for chronic liver disease in China. Recently, many studies have shown that metabolic syndrome is not only the important cause or risk factor for non-alcoholic fatty liver disease, but also closely associated with increased incidence of cirrhosis and liver cancer in patients with alcoholic liver disease, chronic hepatitis B and C, and cryptogenic liver disease. Moreover, chronic liver disease patients with metabolic syndrome have a significantly increased risk of type 2 diabetes and arteriosclerotic cardiovascular disease. These results suggest that hepatologists should pay more attention to the clinical research on the relationship between metabolic syndrome and liver disease and its management.
- metabolic syndrome X /
- obesity, morbid /
- liver diseases

HTML全文

参考文献(27)

[1]FINUCANE MM, STEVENS GA, COWAN MJ, et al.National, regional, and global trends in body-mass index since 1980:systematic analysis of health examination surveys and epidemiological studies with 960 countryyears and“9.1”million participants[J].Lancet, 2011, 377 (9765) :557-567.

[2]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 1) :11-17.

[3]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[4] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.

[5]NEWSOME PN, ALLISON ME, ANDREWS PA, et al.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis[J].Gut, 2012, 61 (4) :484-500.

[6]ALBELDAWI M, AGGARWAL A, MADHWAL S, et al.Cumulative risk of cardiovascular events after orthotopic liver transplantation[J].Liver Transpl, 2012, 18 (3) :370-375.

[7]AGRAWAL S, DARUWALA C.Metabolic syndrome and hepatic resection:improving outcome[J].HPB (Oxford) , 2011, 13 (12) :846-859.

[8]FAN JG, PENG YD.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary Pancreat Dis Int, 2007, 6 (6) :572-578.

[9]FAN JG, CAI XB, LI L, et al.Alcohol consumption and metabolic syndrome among Shanghai adults:A randomized multistage stratified cluster sampling investigation[J].World J Gastroenterol, 2008, 14 (15) :2418-2424.

[10]GUNJI T, MATSUHASHI N, SATO H, et al.Alcohol consumption is inversely correlated with insulin resistance, independent of metabolic syndrome factors and fatty liver diseases[J].J Clin Gastroenterol, 2011, 45 (9) :808-813.

[11]O’SHEA RS, DASARATHY S, McCULLOUGH AJ.Alcoholic liver disease.AASLD practice guideline[J].Hepatology, 2010, 51 (1) :307-328.

[12]JIA QY.Current situation of treatment of alcoholic liver disease[J].Jllin J Tradit Chin Med, 2012, 32 (5) :536-537. (in Chinese) 贾秋颖.酒精性肝病治疗现状[J].吉林中医药, 2012, 32 (5) :536-537.

[13]KIM JH, KIM SY, JUNG ES, et al.Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients[J].Digestion, 2011, 84 (2) :149-155.

[14]BUGIANESI E, SALAMONE F, NEGRO F.The interaction of metabolic factors with HCV infection:does it matter?[J].J Hepatol, 2012, 56 (Suppl 1) :s56-s65.

[15]ADINOLFI LE, RESTIVO L, ZAMPINO R, et al.Chronic HCV infection is a risk of atherosclerosis.Role of HCV and HCV-related steatosis[J].Atherosclerosis, 2012, 221 (2) :496-502.

[16]FAN JG, CHITTURI S.Hepatitis B and fatty liver:causal or coincidental?[J].J Gastroenterol Hepatol, 2008, 23 (5) :779-782.

[17]HSU CS, LIU CH, WANG CC, et al.Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J].J Viral Hepat, 2012, 19 (2) :e48-e57.

[18]WONG VW, WONG GL, CHU WC, et al.Hepatitis B virus infection and fatty liver in the general population[J].J Hepatol, 2012, 56 (3) :533-540.

[19]ZHANG Z, PAN Q, DUAN XY, et al.Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J].J Gastroenterol Hepatol, 2012, 27 (12) :1858-1864.

[20]BORENA W, STROHMAIER S, LUKANOVA A, et al.Metabolic risk factors and primary liver cancer in a prospective study of 578, 700 adults[J].Int J Cancer, 2012, 131 (1) :193-200.

[21]WELZEL TM, GRAUBARD BI, ZEUZEM S, et al.Metabolic syndrome increases the risk of primary liver cancer in the United States:a study in the SEER-Medicare database[J].Hepatology, 2011, 54 (2) :463-471.

[22] SHI JP, LU L, QIAN JC, et al.Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B[J].Chin J Hepatol, 2012, 20 (4) :285-288. (in Chinese) 施军平, 陆璐, 钱建成, 等.肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J].中华肝脏病杂志, 2012, 20 (4) :285-288.

[23]FUNG J, YUEN MF, LAI CL.The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection:fact or fiction?[J].Dig Dis Sci, 2013, 58 (1) :20-22.

[24]FAN JG, SAIBARA T, CHITTURI S, et al.What are the risk factors and settings of nonalcoholic fatty liver disease in Asia-Pacific[J].J Gastroenterol Hepatol, 2007, 22 (6) :794-800.

[25]DUAN XY, QIAO L, FAN JG.Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int, 2012, 11 (1) :18-27.

[26]FAN JG, FARRELL GC;Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma.Prevention of hepatocellular carcinoma in non-viral related liver diseases[J].J Gastroenterol Hepatol, 2009, 24 (5) :712-719.

[27] Expert Committee of Fatty Liver Disease, Chinese Medical Doctor Association.Expert recommendations for standardized management of fatty liver disease[J].J Clin Hepatol, 2013, 16 (3) :207-209. (in Chinese) 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].实用肝脏病杂志, 2013, 16 (3) :207-209.

施引文献

资源附件(0)

访问统计